2023
Bradykinin B2 receptor blockade and intradialytic hypotension
Gamboa J, Mambungu C, Clagett A, Nian H, Yu C, Ikizler T, Brown N. Bradykinin B2 receptor blockade and intradialytic hypotension. BMC Nephrology 2023, 24: 134. PMID: 37170244, PMCID: PMC10176680, DOI: 10.1186/s12882-023-03192-4.Peer-Reviewed Original ResearchConceptsBradykinin B2 receptor blockadeB2 receptor blockadeMaintenance hemodialysisBlood pressureReceptor blockersReceptor blockadeIntradialytic hypotensionBradykinin B2 receptor blockerLack of vasoconstrictionProduction of vasodilatorsSystolic blood pressureGroup of patientsCrossover clinical trialCommon clinical complicationHemodynamic effectsClinical complicationsContinuous infusionClinical trialsStratified analysisIcatibantHemodialysisPatientsHypotensionPlaceboCompensatory mechanisms
2022
Proneuropeptide Y and neuropeptide Y metabolites in healthy volunteers and patients with a pheochromocytoma or paraganglioma
Eugster PJ, Maurer J, Vocat C, Abid K, Matter M, Wuerzner G, Trepp R, Fischli S, Henzen C, Kolb W, Bilz S, Sigrist S, Beuschlein F, Nölting S, Reul A, Schütze I, Hubers SA, Brown NJ, Grouzmann E. Proneuropeptide Y and neuropeptide Y metabolites in healthy volunteers and patients with a pheochromocytoma or paraganglioma. Clinica Chimica Acta 2022, 534: 146-155. PMID: 35905838, DOI: 10.1016/j.cca.2022.07.018.Peer-Reviewed Original ResearchConceptsUpper reference limitPlasma free metanephrinesNeuropeptide YSevere kidney impairmentFree metanephrinesNPY3-36Kidney impairmentSympathetic nervesCatecholamine reuptakeVasoconstrictor peptideNPY2-36NPY1-36Early diagnosisHealthy volunteersPPGL patientsAdrenal medullaTumor localizationPatientsNPYReference limitsDiagnostic sensitivityPPGLsGold standardReference intervalsPheochromocytoma
2021
Active B-Type Natriuretic Peptide Measured by Mass Spectrometry and Response to Sacubitril/Valsartan
Dillon EM, Wei SD, Gupta DK, Nian H, Rodibaugh BS, Bachmann KN, Naftilan AJ, Stevenson LW, Brown NJ. Active B-Type Natriuretic Peptide Measured by Mass Spectrometry and Response to Sacubitril/Valsartan. Journal Of Cardiac Failure 2021, 27: 1231-1239. PMID: 34133968, PMCID: PMC8578199, DOI: 10.1016/j.cardfail.2021.05.026.Peer-Reviewed Original ResearchConceptsSacubitril/valsartanSacubitril/valsartan treatmentHeart failureBNP1-32NT-proBNPValsartan treatmentActive B-type natriuretic peptideEnd-stage renal diseaseB-type natriuretic peptideNT-proBNP immunoassaysPg/mLRenal diseaseNatriuretic peptideBNP productionHealthy volunteersBNPPg/ValsartanPatientsInhibition of degradationPeptide immunoassayBNP degradationTreatmentImmunoassayMS accounts
2020
Skeletal Muscle Mitochondrial Dysfunction Is Present in Patients with CKD before Initiation of Maintenance Hemodialysis
Gamboa JL, Roshanravan B, Towse T, Keller CA, Falck AM, Yu C, Frontera WR, Brown NJ, Ikizler TA. Skeletal Muscle Mitochondrial Dysfunction Is Present in Patients with CKD before Initiation of Maintenance Hemodialysis. Clinical Journal Of The American Society Of Nephrology 2020, 15: 926-936. PMID: 32591419, PMCID: PMC7341789, DOI: 10.2215/cjn.10320819.Peer-Reviewed Original ResearchMeSH KeywordsAdipose TissueAdultAgedDynaminsFemaleGlomerular Filtration RateHumansMagnetic Resonance ImagingMagnetic Resonance SpectroscopyMaleMiddle AgedMitochondriaMuscle StrengthPhosphocreatinePhysical Functional PerformanceQuadriceps MuscleRenal DialysisRenal Insufficiency, ChronicSeverity of Illness IndexWalk TestConceptsMaintenance hemodialysisMarkers of inflammationAdipose tissue infiltrationOxidative stressPhysical performanceMitochondrial dysfunctionTissue infiltrationMitochondrial functionSkeletal muscle mitochondrial dysfunctionCKD stage 3Poor physical performanceSeverity of CKDMuscle mitochondrial dysfunctionIntermuscular adipose tissueSkeletal muscle biopsiesMagnetic resonance imagingWalk testHigh morbidityPhysical functionPhosphocreatine recoveryMultifactorial etiologyMuscle biopsyCKDHemodialysisPatients
2019
Quantification of Neuropeptide Y and Four of Its Metabolites in Human Plasma by Micro-UHPLC-MS/MS
Vocat C, Dunand M, Hubers SA, Bourdillon N, Millet G, Brown NJ, Wuerzner G, Grouzmann E, Eugster PJ. Quantification of Neuropeptide Y and Four of Its Metabolites in Human Plasma by Micro-UHPLC-MS/MS. Analytical Chemistry 2019, 92: 859-866. PMID: 31790196, PMCID: PMC8541045, DOI: 10.1021/acs.analchem.9b03505.Peer-Reviewed Original ResearchConceptsNeuropeptide YNPY3-36Hypertensive patientsHealthy volunteersConcentrations of NPYEndogenous neuropeptide YHuman plasmaNPY2-36Pathological processesReference intervalsEndogenous peptidesChromatography-tandem mass spectrometryPatientsAcid peptideMS/MSVolunteersMetabolitesInter-assay precisionPeptidesPrototype peptideTandem mass spectrometryDistinct effectsOrthostasisCatecholaminesSubpicomolar concentrations
2017
Angiotensin-converting Enzyme Inhibitor and Other Drug-associated Angioedema
Stone C, Brown NJ. Angiotensin-converting Enzyme Inhibitor and Other Drug-associated Angioedema. Immunology And Allergy Clinics Of North America 2017, 37: 483-495. PMID: 28687104, DOI: 10.1016/j.iac.2017.04.006.Peer-Reviewed Original ResearchConceptsDrug-induced angioedemaEnzyme inhibitorsAngiotensin-converting enzyme inhibitorNon-β-lactam antibioticsNonsteroidal antiinflammatory agentsNonallergic angioedemaSubstance PTherapeutic decisionsAngioedemaAntiinflammatory agentsLactam antibioticsOther DrugΒ-lactam antibioticsDrugsPatientsLeukotrienesBradykininGenetic variantsAntibioticsInhibitorsAngiotensinProstaglandinsAgentsHistamineMainstayHypertension and Type 2 Diabetes Are Associated With Decreased Inhibition of Dipeptidyl Peptidase-4 by Sitagliptin
Wilson JR, Shuey MM, Brown NJ, Devin JK. Hypertension and Type 2 Diabetes Are Associated With Decreased Inhibition of Dipeptidyl Peptidase-4 by Sitagliptin. Journal Of The Endocrine Society 2017, 1: 1168-1178. PMID: 29264572, PMCID: PMC5686657, DOI: 10.1210/js.2017-00312.Peer-Reviewed Original ResearchDPP4 activityHealthy controlsSitagliptin doseSystolic blood pressurePeptidase-4 inhibitorsType 2 diabetesDipeptidyl peptidase-4Blood pressureCrossover fashionMetabolic syndromeCrossover studyMultivariable analysisDPP4 inhibitionDPP4 inhibitorsHypertensionPlaceboPeptidase-4High dosesSitagliptinT2DMDecreased inhibitionPatientsLaboratory dataInfluences responseDiabetes
2013
The Effect of Reducing Maximum Shift Lengths to 16 Hours on Internal Medicine Interns’ Educational Opportunities
Theobald CN, Stover DG, Choma NN, Hathaway J, Green JK, Peterson NB, Sponsler KC, Vasilevskis EE, Kripalani S, Sergent J, Brown NJ, Denny JC. The Effect of Reducing Maximum Shift Lengths to 16 Hours on Internal Medicine Interns’ Educational Opportunities. Academic Medicine 2013, 88: 512-518. PMID: 23425987, PMCID: PMC3638874, DOI: 10.1097/acm.0b013e318285800f.Peer-Reviewed Original ResearchConceptsDuty hour restrictionsMaximum shift lengthsInternal medicine internsHour restrictionsVanderbilt University Medical CenterUniversity Medical CenterCommon presenting problemMedicine internsMore patientsUnique patientsInpatient encountersMorning report conferencesMedian numberMedical CenterProgress notesClinical exposureProcedural experienceShift lengthPresenting problemPatientsMore historyHoursExposureAttendanceInterns
2012
Obesity and Oxidative Stress Predict AKI after Cardiac Surgery
Billings FT, Pretorius M, Schildcrout JS, Mercaldo ND, Byrne JG, Ikizler TA, Brown NJ. Obesity and Oxidative Stress Predict AKI after Cardiac Surgery. Journal Of The American Society Of Nephrology 2012, 23: 1221-1228. PMID: 22626819, PMCID: PMC3380645, DOI: 10.1681/asn.2011090940.Peer-Reviewed Original ResearchMeSH KeywordsAcute Kidney InjuryAgedAngiotensin-Converting Enzyme InhibitorsBiomarkersBody Mass IndexCardiac Surgical ProceduresDiureticsF2-IsoprostanesFemaleHumansInterleukin-6MaleMiddle AgedObesityOxidative StressPlasminogen Activator Inhibitor 1Postoperative ComplicationsRamiprilRandomized Controlled Trials as TopicRisk FactorsSignal TransductionSpironolactone
2011
This is not Dr. Conn's aldosterone anymore.
Brown NJ. This is not Dr. Conn's aldosterone anymore. Transactions Of The American Clinical And Climatological Association 2011, 122: 229-43. PMID: 21686229, PMCID: PMC3116341.Peer-Reviewed Original ResearchMeSH KeywordsAldosteroneAngiotensin IIAngiotensin II Type 1 Receptor BlockersAngiotensin-Converting Enzyme InhibitorsAnimalsBlood PressureCytochrome P-450 CYP11B2Disease Models, AnimalEnzyme InhibitorsFibrosisGene Expression RegulationHumansHyperaldosteronismInflammation MediatorsKidneyLigandsMiceMineralocorticoid Receptor AntagonistsMyocardiumRatsReceptors, MineralocorticoidSignal TransductionTime FactorsConceptsMR-independent pathwayPrevalence of hyperaldosteronismAngiotensin receptor blockersMineralocorticoid receptor antagonismSecretion of aldosteroneAldosterone-secreting adenomasPro-fibrotic effectsReceptor blockersResistant hypertensionSevere hypertensionAldosterone concentrationRenal injuryEndogenous aldosteroneACE inhibitorsCardiovascular remodelingAngiotensin IIReceptor antagonismHeart diseaseProfibrotic effectsAldosteroneBaseline valuesEnzyme inhibitorsPatientsPotassium homeostasisHypertension
2010
Bradykinin forming capacity of oversulfated chondroitin sulfate contaminated heparin in vitro
Adam A, Montpas N, Keire D, Désormeaux A, Brown NJ, Marceau F, Westenberger B. Bradykinin forming capacity of oversulfated chondroitin sulfate contaminated heparin in vitro. Biomaterials 2010, 31: 5741-5748. PMID: 20427081, PMCID: PMC2896062, DOI: 10.1016/j.biomaterials.2010.03.074.Peer-Reviewed Original ResearchConceptsContact system activationAnaphylactoid reactionsOversulfated chondroitin sulfateSystem activationSevere anaphylactoid reactionPlasma contact systemHuman plasmaInflammatory peptidesChondroitin sulfateEnzyme inhibitorsBK releaseDrug AdministrationBradykininHeparinSignificant correlationDefinitive evidenceDextran sulfatePlasma dilutionActivationConclusionPatientsPathophysiologyKininsAdministrationPlasma
2009
Letter by Brown and Pretorius Regarding Article, “Effect of Sulfaphenazole on Tissue Plasminogen Activator Release in Normotensive Subjects and Hypertensive Patients”
Brown NJ, Pretorius M. Letter by Brown and Pretorius Regarding Article, “Effect of Sulfaphenazole on Tissue Plasminogen Activator Release in Normotensive Subjects and Hypertensive Patients”. Circulation 2009, 120: e159; author reply e160. PMID: 19901200, DOI: 10.1161/circulationaha.109.874743.Peer-Reviewed Original Research
2007
Aldosterone and end-organ damage
Marney AM, Brown NJ. Aldosterone and end-organ damage. Clinical Science 2007, 113: 267-278. PMID: 17683282, DOI: 10.1042/cs20070123.Peer-Reviewed Original ResearchConceptsMR antagonismBlood pressureEndothelial functionMyocardial infarctionGlucose homeostasisRapid non-genomic effectsEnd-organ damageImpairs endothelial functionNon-genomic effectsNon-genomic pathwaysResistant hypertensionAldosterone concentrationEndothelial dysfunctionRenal injuryDiabetic patientsMetabolic syndromeSleep apnoeaSubsequent fibrosisMR activationSodium retentionCardiac fibrosisCardiovascular remodellingBody of evidenceAldosteronePatients
2003
Eplerenone
Brown NJ. Eplerenone. Circulation 2003, 107: 2512-2518. PMID: 12756192, DOI: 10.1161/01.cir.0000071081.35693.9a.Peer-Reviewed Original ResearchConceptsAldosterone receptor antagonistsReceptor antagonistMineralocorticoid receptor-dependent mechanismSelective aldosterone receptor antagonistAldosterone receptor antagonismRole of aldosteroneCongestive heart failureTreatment of hypertensionReceptor-dependent mechanismAntiandrogenic side effectsRenal injuryHeart failureReceptor antagonismCardiovascular toxicityClinical trialsSide effectsAnimal studiesEplerenoneAldosteroneAntagonistHypertensionPatientsSpironolactoneInjuryMortality
2001
Possible Medication Errors in Home Healthcare Patients
Meredith S, Feldman P, Frey D, Hall K, Arnold K, Brown N, Ray W. Possible Medication Errors in Home Healthcare Patients. Journal Of The American Geriatrics Society 2001, 49: 719-724. PMID: 11454109, DOI: 10.1046/j.1532-5415.2001.49147.x.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overCross-Sectional StudiesDrug Therapy, CombinationFemaleGuideline AdherenceHealth Services ResearchHome Care ServicesHumansLinear ModelsLogistic ModelsLos AngelesMaleMedication ErrorsNew York CityPractice Guidelines as TopicRetrospective StudiesRisk AssessmentRisk FactorsRisk ManagementTotal Quality ManagementUnnecessary ProceduresConceptsPossible medication errorsHome healthcare patientsBeers criteriaMedication errorsHealthcare patientsMedication useHealth criteriaPotential medication problemsMedication-related problemsNumber of medicationsPatients age 65Cross-sectional surveyHome healthcare agenciesMore medicationsOlder patientsMedication problemsPanel criteriaPatientsStudy subjectsMore drugsMedicationsAge 65Older peopleVulnerable populationsHealthcare agencies
1999
Serum metabolism of bradykinin and des-Arg9-bradykinin in patients with angiotensin-converting enzyme inhibitor-associated angioedema
Blais C, Rouleau J, Brown N, Lepage Y, Spence D, Munoz C, Friborg J, Geadah D, Gervais N, Adam A. Serum metabolism of bradykinin and des-Arg9-bradykinin in patients with angiotensin-converting enzyme inhibitor-associated angioedema. Immunopharmacology 1999, 43: 293-302. PMID: 10596866, DOI: 10.1016/s0162-3109(99)00133-2.Peer-Reviewed Original ResearchConceptsDes-Arg9AE patientsC subjectsLife-threatening adverse reactionsEnzyme (ACE) inhibitor-associated angioedemaMetabolism of bradykininLocal inflammatory reactionEnzyme defectPreincubation of seraBK metabolismSensitive enzyme immunoassayB1 agonistSerum metabolismAdverse reactionsControl subjectsInflammatory reactionACEIAngioedemaAbnormal metabolismPatientsEnzyme inhibitorsSynthetic bradykininControl seraBradykininEnzyme immunoassayRole of Angiotensin II in Coagulation and Fibrinolysis
Brown N, Vaughan D. Role of Angiotensin II in Coagulation and Fibrinolysis. Heart Failure Reviews 1999, 3: 193-198. DOI: 10.1023/a:1009757416302.Peer-Reviewed Original ResearchAntithrombotic effectAngiotensin type 1 receptor antagonistType 1 receptor antagonistVascular fibrinolytic balanceRenin-angiotensin systemTissue plasminogen activatorHypertensive patientsInhibitor PAI-1Angiotensin IIFibrinolytic balanceReceptor antagonistVasculoprotective propertiesPlatelet functionEnzyme inhibitorsPAI-1Plasminogen activatorMultiple mechanismsFibrinolysisSubstantial evidenceRecent studiesAngiotensinPatientsProstanoidsAntagonist
1997
Recurrent Angiotensin-Converting Enzyme Inhibitor—Associated Angioedema
Brown N, Snowden M, Griffin M. Recurrent Angiotensin-Converting Enzyme Inhibitor—Associated Angioedema. JAMA 1997, 278: 232-233. DOI: 10.1001/jama.1997.03550030072037.Peer-Reviewed Original ResearchConceptsACE inhibitor useAngiotensin converting enzyme (ACE) inhibitorsACE inhibitorsInhibitor useRecurrent angioedemaEnzyme inhibitorsEpisodes of angioedemaRate of angioedemaRetrospective cohort studyDiagnosis of angioedemaRisk of angioedemaTennessee Medicaid programAngioedema recurrencesCohort studySerious morbidityRecurrent episodesMedical recordsAssociated angioedemaMultiple recurrencesMedicaid enrolleesAngioedemaPatientsRecurrenceNumber of causesMedicaid programRecurrent angiotensin-converting enzyme inhibitor--associated angioedema.
Brown N, Snowden M, Griffin M. Recurrent angiotensin-converting enzyme inhibitor--associated angioedema. JAMA 1997, 278: 232-3. PMID: 9218671, DOI: 10.1001/jama.278.3.232.Peer-Reviewed Original ResearchConceptsACE inhibitor useACE inhibitorsInhibitor useRecurrent angioedemaEnzyme inhibitorsAngiotensin-converting enzyme inhibitorEpisodes of angioedemaRate of angioedemaRetrospective cohort studyDiagnosis of angioedemaRisk of angioedemaTennessee Medicaid programAngioedema recurrencesCohort studySerious morbidityRecurrent episodesMedical recordsAssociated angioedemaMultiple recurrencesMedicaid enrolleesAngioedemaPatientsRecurrenceNumber of causesMedicaid program